OVERVIEW OF REQUIRED EVIDENCE AND CONSIDERATIONS FOR PRIORITISING

Evidence to be provided		Considerations for priority setting
Substance family		
Substance		
CAS number		
1. Evidence of exposure	• Yes/No – give evidence	1. Quality and quantity of human exposure evidence (provider, consistency, use) 2. Geographical extent of human exposure (hotspots, regional, EU wide…) 3. Population groups exposed (workers, consumers, children (+)) 4. Source (e.g. diet, workplace) and route of exposure (oral, dermal, inhalation…) 5. Emerging substance, mainly environmental monitoring data available
2. Evidence of potential health impact	• Yes/No –indicate which impact and evidence	1. Established hazard(s), incl. PBT characteristics, and link to human health effects including severity of effect and irreversibility 2. Evidence involving human data 3. Data from animal/in vitro models considered relevant for human health (if available) 4. Population groups concerned by the health impact (children (+)) 5. Emerging substance: uncertainties in hazard data, reason to apply precautionary principle
3. Evidence of public concern	• Yes/No – list evidence	1. Public demand for action and its credibility
4. Rationale for action/inaction (regulatory aspects)	• Yes/No – please indicate relevant legislation, existing opinions, open questions, policy needs and ability to act	1. Regulatory status of substance: banned or restricted substances are of lower priority unless there is risk of exposure or other special reason for monitoring 2. Requirement for public health action 3. Supporting information for the development/update of legislation 4. Monitoring of effectiveness of regulatory measures to reduce exposure
5. Rational for action/inaction (technical aspects)	• Yes/No – list evidence	1. Technical feasibility and available methods for biomonitoring the substance 2. Availability and quality of required background knowledge 3. Information on risk assessment capacity 4. Realistic time frame to allow to respond to policy need
6. Action expected from EJP	• Describe what the EHBMI EJP should be doing and how the expected results will support policy making	1. Concreteness of action required 2. Going beyond the state-of-art (incl. avoiding duplication of efforts) 3. Use of HBM data & methods is justified 4. Cost/benefit ratio estimate

TEMPLATE

Evidence to be provided	
Substance family	
Substance	
CAS number	
1. Evidence of exposure	• Yes/No – evidence
2. Evidence of potential health impact	• Yes/No – indicate which impact and evidence
3. Evidence of public concern	• Yes/No – list evidence
4. Rationale for action/inaction (regulatory aspects)	• Yes/No – please indicate relevant legislation, open questions & policy needs and ability to act
5. Rational for action/inaction (technical aspects)	• Yes/No – list evidence
5. Action expected from EJP	• Describe what the EHBMI EJP should be doing and how the expected results will support policy making